FibroGen
Aileen (Cuihua) Huang currently serves as a Senior Medical Manager at FibroGen, Inc. since June 2021, bringing extensive experience from previous roles such as Senior Medical Manager at Sanofi and Senior Scientist at RB. Aileen has also held significant positions at Nutricia Medical Nutrition as a Senior MA Specialist and Supervisor, as well as at the Shanghai Municipal Center for Disease Control and Prevention as a Physician. Aileen began a medical career as an Intern at the Xinhua Hospital affiliated with Shanghai Jiaotong University. Aileen holds a Master of Medicine in Clinical Nutrition from Shanghai Jiao Tong University and a Bachelor of Medicine in Preventive Medicine from China Medical University.
This person is not in any offices
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.